These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 19124243)

  • 1. 3,4-Disubstituted isothiazoles: novel potent inhibitors of VEGF receptors 1 and 2.
    Kiselyov AS; Semenova M; Semenov VV
    Bioorg Med Chem Lett; 2009 Feb; 19(4):1195-8. PubMed ID: 19124243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 4-(Azolylphenyl)-phthalazin-1-amines: Novel inhibitors of VEGF receptors I and II.
    Kiselyov AS; Semenov VV; Milligan D
    Chem Biol Drug Des; 2006 Dec; 68(6):308-13. PubMed ID: 17177892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ortho-Substituted azoles as selective and dual inhibitors of VEGF receptors 1 and 2.
    Kiselyov AS; Piatnitski EL; Samet AV; Kisliy VP; Semenov VV
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1369-75. PubMed ID: 17188873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1-(Azolyl)-4-(aryl)-phthalazines: novel potent inhibitors of VEGF receptors I and II.
    Kiselyov AS; Semenova M; Semenov VV; Piatnitski EL
    Chem Biol Drug Des; 2006 Nov; 68(5):250-5. PubMed ID: 17177884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors of VEGF receptors-1 and -2 based on the 2-((pyridin-4-yl)ethyl)pyridine template.
    Kiselyov AS; Semenova M; Semenov VV; Milligan D
    Bioorg Med Chem Lett; 2006 Apr; 16(7):1913-9. PubMed ID: 16460936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arylphthalazines. Part 2: 1-(Isoquinolin-5-yl)-4-arylamino phthalazines as potent inhibitors of VEGF receptors I and II.
    Duncton MA; Piatnitski EL; Katoch-Rouse R; Smith LM; Kiselyov AS; Milligan DL; Balagtas C; Wong WC; Kawakami J; Doody JF
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1579-81. PubMed ID: 16386418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (1,2,3-Triazol-4-yl)benzenamines: synthesis and activity against VEGF receptors 1 and 2.
    Kiselyov AS; Semenova M; Semenov VV
    Bioorg Med Chem Lett; 2009 Mar; 19(5):1344-8. PubMed ID: 19188066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-(Aryl)-4-(azolylethyl)thiazole-5-carboxamides: novel potent inhibitors of VEGF receptors I and II.
    Kiselyov AS; Piatnitski E; Semenova M; Semenov VV
    Bioorg Med Chem Lett; 2006 Feb; 16(3):602-6. PubMed ID: 16275072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hetaryl imidazoles: a novel dual inhibitors of VEGF receptors I and II.
    Kiselyov AS; Semenova M; Semenov VV; Piatnitski E; Ouyang S
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1440-4. PubMed ID: 16321531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2-((1H-Azol-1-yl)methyl)-N-arylbenzamides: novel dual inhibitors of VEGFR-1/2 kinases.
    Kiselyov AS; Semenova M; Semenov VV; Piatnitski E
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1726-30. PubMed ID: 16364640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A selective and oral small molecule inhibitor of vascular epithelial growth factor receptor (VEGFR)-2 and VEGFR-1 inhibits neovascularization and vascular permeability.
    Patel N; Sun L; Moshinsky D; Chen H; Leahy KM; Le P; Moss KG; Wang X; Rice A; Tam D; Laird AD; Yu X; Zhang Q; Tang C; McMahon G; Howlett A
    J Pharmacol Exp Ther; 2003 Sep; 306(3):838-45. PubMed ID: 12766257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arylphthalazines: identification of a new phthalazine chemotype as inhibitors of VEGFR kinase.
    Piatnitski EL; Duncton MA; Kiselyov AS; Katoch-Rouse R; Sherman D; Milligan DL; Balagtas C; Wong WC; Kawakami J; Doody JF
    Bioorg Med Chem Lett; 2005 Nov; 15(21):4696-8. PubMed ID: 16143524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1H-1,2,4-triazol-3-yl-anilines: novel potent inhibitors of vascular endothelial growth factor receptors 1 and 2.
    Kiselyov AS; Piatnitski E; Milligan D; Ouyang X
    Chem Biol Drug Des; 2007 May; 69(5):331-7. PubMed ID: 17539825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Traceless solid-phase synthesis of 2-aminothiazoles: receptor tyrosine kinase inhibitors with dual selectivity for Tie-2 and VEGFR-2.
    Stieber F; Mazitschek R; Soric N; Giannis A; Waldmann H
    Angew Chem Int Ed Engl; 2002 Dec; 41(24):4757-61. PubMed ID: 12481350
    [No Abstract]   [Full Text] [Related]  

  • 15. Vascular endothelial growth factor in chronic rat allograft nephropathy.
    Malmström NK; Kallio EA; Rintala JM; Nykänen AI; Räisänen-Sokolowski AK; Paavonen T; Lemström KB; Koskinen PK
    Transpl Immunol; 2008 May; 19(2):136-44. PubMed ID: 18503889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent 2-[(pyrimidin-4-yl)amine}-1,3-thiazole-5-carbonitrile-based inhibitors of VEGFR-2 (KDR) kinase.
    Sisko JT; Tucker TJ; Bilodeau MT; Buser CA; Ciecko PA; Coll KE; Fernandes C; Gibbs JB; Koester TJ; Kohl N; Lynch JJ; Mao X; McLoughlin D; Miller-Stein CM; Rodman LD; Rickert KW; Sepp-Lorenzino L; Shipman JM; Thomas KA; Wong BK; Hartman GD
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1146-50. PubMed ID: 16368234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2-Hydroxy-4,6-diamino-[1,3,5]triazines: a novel class of VEGF-R2 (KDR) tyrosine kinase inhibitors.
    Baindur N; Chadha N; Brandt BM; Asgari D; Patch RJ; Schalk-Hihi C; Carver TE; Petrounia IP; Baumann CA; Ott H; Manthey C; Springer BA; Player MR
    J Med Chem; 2005 Mar; 48(6):1717-20. PubMed ID: 15771417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
    Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
    Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological evaluation of benzamides and benzamidines as selective inhibitors of VEGFR tyrosine kinases.
    Nakamura H; Sasaki Y; Uno M; Yoshikawa T; Asano T; Ban HS; Fukazawa H; Shibuya M; Uehara Y
    Bioorg Med Chem Lett; 2006 Oct; 16(19):5127-31. PubMed ID: 16893647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors.
    Potashman MH; Bready J; Coxon A; DeMelfi TM; DiPietro L; Doerr N; Elbaum D; Estrada J; Gallant P; Germain J; Gu Y; Harmange JC; Kaufman SA; Kendall R; Kim JL; Kumar GN; Long AM; Neervannan S; Patel VF; Polverino A; Rose P; Plas Sv; Whittington D; Zanon R; Zhao H
    J Med Chem; 2007 Sep; 50(18):4351-73. PubMed ID: 17696416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.